Photoimmunotherapy for Managing Recurrent Laryngeal Cancer Cervical Lesions: A Case Report

Photoimmunotherapy (PIT) targets and destroys tumor cells through irradiation with 690-nm red light after the administration of cetuximab sarotalocan sodium, which contains IRDye700DX bound to cetuximab. In Japan, PIT is a new treatment that is covered by insurance only for unresectable head and nec...

Full description

Saved in:
Bibliographic Details
Published in:Case reports in oncology 2022-02, Vol.15 (1), p.34-39
Main Authors: Okamoto, Isaku, Okada, Takuro, Tokashiki, Kunihiko, Tsukahara, Kiyoaki
Format: Article
Language:English
Subjects:
Brain cancer
Cancer therapies
Carotid arteries
Case Report
Case reports
Catheters
cetuximab sarotalocan sodium
Committees
Head & neck cancer
head and neck carcinoma
Laryngeal cancer
Lasers
Lymphatic system
Metastasis
Monoclonal antibodies
photoimmunotherapy
photosensitivity
Sodium
Surgery
Targeted cancer therapy
Tomography
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Photoimmunotherapy (PIT) targets and destroys tumor cells through irradiation with 690-nm red light after the administration of cetuximab sarotalocan sodium, which contains IRDye700DX bound to cetuximab. In Japan, PIT is a new treatment that is covered by insurance only for unresectable head and neck cancers. However, this treatment has conditional early approval. There have been no case reports describing the efficacy of this treatment in a real-world setting thus far. We report our experience with PIT for head and neck cancer. A 76-year-old man with laryngeal cancer underwent radiation therapy and surgery. Skin involvement in the right submandibular region was subsequently noted. We diagnosed local recurrence and performed PIT for this lesion. Partial response was achieved after the first PIT session, and progressive disease was diagnosed after the second session. Many aspects of PIT remain unclear and should, therefore, be clarified in further research. Despite this uncertainty, PIT may become an effective treatment strategy for head and neck cancer if the patient selection criteria are delineated.
ISSN:1662-6575
1662-6575
DOI:10.1159/000521435